CA2664043A1 - Use of taq polymerase mutant enzymes for dna amplification in the presence of pcr inhibitors - Google Patents
Use of taq polymerase mutant enzymes for dna amplification in the presence of pcr inhibitors Download PDFInfo
- Publication number
- CA2664043A1 CA2664043A1 CA002664043A CA2664043A CA2664043A1 CA 2664043 A1 CA2664043 A1 CA 2664043A1 CA 002664043 A CA002664043 A CA 002664043A CA 2664043 A CA2664043 A CA 2664043A CA 2664043 A1 CA2664043 A1 CA 2664043A1
- Authority
- CA
- Canada
- Prior art keywords
- soil
- pcr
- polymerase
- dye
- assay mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 28
- 102000004190 Enzymes Human genes 0.000 title description 42
- 108090000790 Enzymes Proteins 0.000 title description 42
- 108010006785 Taq Polymerase Proteins 0.000 title description 16
- 230000004544 DNA amplification Effects 0.000 title description 2
- 239000002689 soil Substances 0.000 claims abstract description 123
- 239000008280 blood Substances 0.000 claims abstract description 80
- 210000004369 blood Anatomy 0.000 claims abstract description 80
- 238000000034 method Methods 0.000 claims abstract description 67
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 56
- 239000000975 dye Substances 0.000 claims abstract description 55
- 238000003753 real-time PCR Methods 0.000 claims abstract description 32
- 238000002944 PCR assay Methods 0.000 claims abstract description 24
- 238000003556 assay Methods 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 37
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 239000007850 fluorescent dye Substances 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 claims description 17
- 239000004021 humic acid Substances 0.000 claims description 17
- 238000006467 substitution reaction Methods 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 229960003237 betaine Drugs 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- -1 PICO Chemical compound 0.000 claims description 3
- MZZINWWGSYUHGU-UHFFFAOYSA-J ToTo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 MZZINWWGSYUHGU-UHFFFAOYSA-J 0.000 claims description 3
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 claims description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims description 2
- 229960005542 ethidium bromide Drugs 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 abstract description 29
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 abstract description 29
- 238000001514 detection method Methods 0.000 abstract description 20
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 108020004414 DNA Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 241000193755 Bacillus cereus Species 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000011880 melting curve analysis Methods 0.000 description 10
- 239000003068 molecular probe Substances 0.000 description 9
- 230000000171 quenching effect Effects 0.000 description 8
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 239000001046 green dye Substances 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000011897 real-time detection Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 101150017501 CCR5 gene Proteins 0.000 description 2
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 238000000658 coextraction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000002509 fulvic acid Substances 0.000 description 2
- 229940095100 fulvic acid Drugs 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002804 saturated mutagenesis Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82569206P | 2006-09-14 | 2006-09-14 | |
| US60/825,692 | 2006-09-14 | ||
| PCT/US2007/078571 WO2008034110A2 (en) | 2006-09-14 | 2007-09-14 | Use of taq polymerase mutant enzymes for dna amplification in the presence of pcr inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2664043A1 true CA2664043A1 (en) | 2008-03-20 |
Family
ID=39184635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002664043A Abandoned CA2664043A1 (en) | 2006-09-14 | 2007-09-14 | Use of taq polymerase mutant enzymes for dna amplification in the presence of pcr inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110027832A1 (https=) |
| EP (1) | EP2061894A4 (https=) |
| JP (2) | JP5457184B2 (https=) |
| AU (1) | AU2007296180A1 (https=) |
| CA (1) | CA2664043A1 (https=) |
| WO (1) | WO2008034110A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7462475B2 (en) | 2004-05-20 | 2008-12-09 | Dna Poleymerase Technology, Inc. | Use of whole blood in PCR reactions |
| US20090305345A1 (en) | 2006-10-23 | 2009-12-10 | Medical Research Council | Polymerase |
| JP2011097828A (ja) * | 2008-07-09 | 2011-05-19 | Beckman Coulter Inc | 全血試料の前処理方法及び核酸増幅方法 |
| WO2010062777A2 (en) * | 2008-11-03 | 2010-06-03 | Kapabiosystems | Modified type a dna polymerases |
| FI20095729A0 (fi) * | 2009-06-26 | 2009-06-26 | Finnzymes Oy | Menetelmä deoksiribonukleiinihappojen kvantitatiiviseen PCR-monistukseen PCR-inhibiittoreita sisältävästä näytteestä |
| WO2011014885A1 (en) * | 2009-07-31 | 2011-02-03 | Agilent Technologies, Inc. | Thermostable type-a dna polymerase mutants with increased polymerization rate and resistance to inhibitors |
| FI20096013A7 (fi) * | 2009-10-02 | 2011-04-03 | Finnzymes Oy | Menetelmä reaktioseoksen valmistelemiseksi ja tähän liittyvät tuotteet |
| JP5926248B2 (ja) | 2010-06-18 | 2016-05-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 増大した３’末端ミスマッチ識別能を有するｄｎａポリメラーゼ |
| WO2011157432A1 (en) | 2010-06-18 | 2011-12-22 | Roche Diagnostics Gmbh | Dna polymerases with increased 3'-mismatch discrimination |
| EP2582806B1 (en) | 2010-06-18 | 2015-12-16 | Roche Diagnostics GmbH | Dna polymerases with increased 3'-mismatch discrimination |
| WO2011157434A1 (en) | 2010-06-18 | 2011-12-22 | Roche Diagnostics Gmbh | Dna polymerases with increased 3'-mismatch discrimination |
| US8759062B2 (en) | 2010-06-18 | 2014-06-24 | Roche Molecular Systems, Inc. | DNA polymerases with increased 3′- mismatch discrimination |
| WO2011157436A1 (en) | 2010-06-18 | 2011-12-22 | Roche Diagnostics Gmbh | Dna polymerases with increased 3'-mismatch discrimination |
| ES2536252T3 (es) | 2010-06-18 | 2015-05-21 | F. Hoffmann-La Roche Ag | ADN polimerasas con diferenciación de desapareamientos 3' aumentada |
| CA2802239C (en) | 2010-06-18 | 2016-08-23 | F. Hoffmann-La Roche Ag | Dna polymerases with increased 3'-mismatch discrimination |
| WO2012097318A2 (en) | 2011-01-14 | 2012-07-19 | Kap Abiosystems | Modified dna polymerases for improved amplification |
| US8765435B2 (en) | 2011-02-15 | 2014-07-01 | Roche Molecular Systems, Inc. | DNA polymerases with increased 3′-mismatch discrimination |
| JP5847200B2 (ja) | 2011-02-15 | 2016-01-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 増大した３’末端ミスマッチ識別能を有するｄｎａポリメラーゼ |
| ES2561885T3 (es) | 2011-04-11 | 2016-03-01 | F. Hoffmann-La Roche Ag | ADN polimerasas de actividad mejorada |
| GB201113430D0 (en) | 2011-08-03 | 2011-09-21 | Fermentas Uab | DNA polymerases |
| US11208636B2 (en) | 2011-08-10 | 2021-12-28 | Life Technologies Corporation | Polymerase compositions, methods of making and using same |
| US20130040365A1 (en) | 2011-08-10 | 2013-02-14 | Life Technologies Corporation | Polymerase compositions, methods of making and using same |
| ES2569723T3 (es) | 2011-12-08 | 2016-05-12 | F. Hoffmann-La Roche Ag | Polimerasas de DNA con actividad mejorada |
| ES2668448T3 (es) | 2011-12-08 | 2018-05-18 | F. Hoffmann-La Roche Ag | ADN polimerasas con actividad mejorada |
| CN103998603B (zh) | 2011-12-08 | 2016-05-25 | 霍夫曼-拉罗奇有限公司 | 具有改进活性的dna聚合酶 |
| EP3366769B1 (en) | 2012-10-16 | 2021-02-17 | DNA Polymerase Technology, Inc. | Inhibition-resistant polymerases |
| US9758773B2 (en) * | 2014-02-14 | 2017-09-12 | Agilent Technologies, Inc. | Thermostable type-A DNA polymerase mutant with increased resistance to inhibitors in blood |
| SG11201700456UA (en) | 2014-07-21 | 2017-02-27 | Agency Science Tech & Res | Silica coating on nanoparticles |
| US11091745B2 (en) | 2015-05-12 | 2021-08-17 | Dna Polymerase Technology, Inc. | Mutant polymerases and uses thereof |
| WO2021242041A1 (ko) * | 2020-05-29 | 2021-12-02 | (주)제노텍 | 유전자 변이에 대한 구분성이 향상된 dna 중합효소 변이체 |
| JP7393070B1 (ja) * | 2023-08-04 | 2023-12-06 | 株式会社ゴーフォトン | Ｐｃｒ方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8906091A (en) * | 1990-10-05 | 1992-04-28 | Wayne M. Barnes | Thermostable dna polymerase |
| EP0590327B1 (en) * | 1992-09-11 | 2003-04-09 | F. Hoffmann-La Roche Ag | Detection of nucleic acids in blood |
| US5436149A (en) * | 1993-02-19 | 1995-07-25 | Barnes; Wayne M. | Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension |
| US6818431B1 (en) * | 1995-10-18 | 2004-11-16 | Shanghai Mendel Dna Center Co. Ltd. | DNA polymerase having ability to reduce innate selective discrimination against fluorescent dye-labeled dideoxynucleotides |
| GB0022458D0 (en) | 2000-09-13 | 2000-11-01 | Medical Res Council | Directed evolution method |
| US20060234227A1 (en) | 2002-05-14 | 2006-10-19 | Alexei Slesarev | Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes |
| US20040161767A1 (en) * | 2002-06-28 | 2004-08-19 | Baldwin Brett R. | Detection and quantification of aromatic oxygenase genes by real-time PCR |
| US7417133B2 (en) | 2004-02-27 | 2008-08-26 | Institut Pasteur | Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same |
| US20050260606A1 (en) * | 2004-05-20 | 2005-11-24 | Kermekchiev Milko B | Use of whole blood in PCR reactions |
| US7462475B2 (en) * | 2004-05-20 | 2008-12-09 | Dna Poleymerase Technology, Inc. | Use of whole blood in PCR reactions |
| US20070048748A1 (en) | 2004-09-24 | 2007-03-01 | Li-Cor, Inc. | Mutant polymerases for sequencing and genotyping |
| US20070111234A1 (en) * | 2005-09-12 | 2007-05-17 | Christian Birkner | Detection of biological DNA |
-
2007
- 2007-09-14 CA CA002664043A patent/CA2664043A1/en not_active Abandoned
- 2007-09-14 WO PCT/US2007/078571 patent/WO2008034110A2/en not_active Ceased
- 2007-09-14 AU AU2007296180A patent/AU2007296180A1/en not_active Abandoned
- 2007-09-14 JP JP2009528513A patent/JP5457184B2/ja not_active Expired - Fee Related
- 2007-09-14 EP EP07842556A patent/EP2061894A4/en not_active Withdrawn
-
2009
- 2009-03-16 US US12/441,521 patent/US20110027832A1/en not_active Abandoned
-
2013
- 2013-10-04 JP JP2013209506A patent/JP2014054254A/ja active Pending
-
2015
- 2015-06-23 US US14/746,982 patent/US9796965B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008034110A9 (en) | 2013-09-12 |
| AU2007296180A1 (en) | 2008-03-20 |
| WO2008034110A2 (en) | 2008-03-20 |
| US20150368624A1 (en) | 2015-12-24 |
| JP5457184B2 (ja) | 2014-04-02 |
| JP2010503413A (ja) | 2010-02-04 |
| WO2008034110A3 (en) | 2008-12-24 |
| US20110027832A1 (en) | 2011-02-03 |
| US9796965B2 (en) | 2017-10-24 |
| JP2014054254A (ja) | 2014-03-27 |
| EP2061894A4 (en) | 2010-05-05 |
| EP2061894A2 (en) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5457184B2 (ja) | Ｐｃｒ阻害物質の存在下におけるｄｎａ増幅のためのｔａｑポリメラーゼ変異体酵素の使用 | |
| US8470563B2 (en) | Use of whole blood in PCR reactions | |
| Dobosy et al. | RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers | |
| EP0726324B1 (en) | Use of exonuclease and/or glycosylase as supplements to anti-polymerase antibody to increase specificity in polymerase chain reaction | |
| JPH09107997A (ja) | 標的核酸の増幅方法及び増幅キット並びにｐｃｒ用組成物 | |
| KR20110102841A (ko) | 실시간 ｐｃｒ을 위한 핵산 주형의 제조 | |
| US11920185B2 (en) | Method of inactivating microbes by citraconic anhydride | |
| KR102030244B1 (ko) | 뎅기 바이러스 검출용 올리고뉴클레오티드 세트 및 이의 용도 | |
| EP2898095B1 (en) | Compositions and methods for detection of clostridium difficile | |
| CN105705660B (zh) | 使用重叠引物和熔解探针检测单核苷酸多态性 | |
| WO2009140497A1 (en) | Enzyme reagents for amplification of polynucleotides in the presence of inhibitors | |
| CN108291252B (zh) | 稳定特定rna的通用方法 | |
| CN107653336B (zh) | 用于鉴定小麦春化基因vrn-b1的引物及其应用 | |
| US20130029316A1 (en) | Method for real-time detection of west nile virus using a cleavable chimeric probe | |
| US20120052497A1 (en) | Method of simultaneously amplifying target sequences from salmonella spp. and e. coli o157:h7 and kit therefor | |
| Chen et al. | High‐throughput detection of highly benzimidazole‐resistant allele E198A with mismatch primers in allele‐specific real‐time polymerase chain reaction | |
| WO2021262013A1 (en) | Bst-nec dna fusion polymerase for use in isothermal replication of specific sars cov-2 virus sequences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20150729 |